In addition, as noted, there was a nonsignificant trend for the patients who were excluded due to poor image quality to be older with increased BMIs.
2
—
—
The sentences
26 For patients with transthyretin cardiac amyloidosis specifically, an expert consensus panel recommends that an absolute change of ≥1% in a year could be considered significant. 27 In patients with heart failure with reduced LVEF, Mazzetti et al 28 showed that use of sacubitril–valsartan improved LV‐GLS at 6 months from −6.9% to −7.9%, a relative improvement of 14%.